相关实验视频
Updated: Sep 14, 2025

06:41
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
12.6K
通过体外膜氧化救出阿姆洛迪平过量服用:一个病例报告
Hong Ding1, Hui Wang2, Zi-Yan Wang1
1Department of Intensive Care, Affiliated Hospital of Chengde Medical University, Chengde, China.
Medicine
|July 23, 2025
概括
严重的阿姆洛迪平过量服用可能会导致耐火性休克. 身体外膜氧化 (ECMO) 提供了关键的支持,导致在严重的通道阻断剂毒性病例中成功恢复.
科学领域:
- 心脏病学 心脏病学
- 毒理学 毒理学 毒理学
- 关键护理医学 关键护理医学
背景情况:
- 阿姆洛迪平是一种通道阻塞剂,是一种常见的抗高血压药物.
- 严重的阿姆洛迪平毒性可能导致耐火性休克,对标准治疗无反应.
研究的目的:
- 报告一种严重的阿姆洛迪平过量剂和耐火性休克病例.
- 突出体外膜氧化 (ECMO) 在处理这些关键病例中的作用.
主要方法:
- 一名32岁的女性摄入了84片 (5毫克每片) 的阿姆洛迪平.
- 患者出现了阿姆洛迪平过量服用和耐火性休克.
- 治疗包括ECMO,机械呼吸和持续的置换疗法.
主要成果:
- 患者成功地从ECMO和机械通风中断奶.
- 在CT扫描上观察到肺部排泄物完全消失.
- 患者在稳定的状态下出院.
结论:
- 早期ECMO启动对于严重通道阻塞毒性的血液动力学稳定至关重要.
- 当传统疗法失败时,ECMO提供了一个可行的替代方案.
- 这一案例强调了先进生命支持在管理药物过量中的重要性.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
79
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
79
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
320
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
320
Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
Acute Coronary Syndrome IV: Interprofessional Care
30
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
30
Heart Failure VI: Adjunct Therapies
29
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
29
Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23

